1. A pharmaceutically acceptable composition having a pH of from about 9.1 to about 9.8, comprising: active ingredients comprising carbidopa and at least about 4 wt.% Levodopa； arginine and optionally meglumine, preferably said composition comprises (i) from about 4 to about 12%, or from about 5% to about 30 wt.% levodopa； or (ii) from about 1 to about 6%, or from about 1 to about 2 wt.% carbidopa； or (iii) from about 10 to about 35 wt.% arginine. 2. The pharmaceutically acceptable composition according to claim 1, characterized in that the molar ratio of active components to arginine is from about 1: 1.8 to about 1: 3.5 or about 1: 2.3.3. The pharmaceutically acceptable composition according to claim 1, containing meglumine, preferably the molar ratio of active components to arginine is from about 1: 1.1 to about 1: 1.9, and the molar ratio of active components to meglumine is from about 1: 0.3 to about 1: 1.5.4. The pharmaceutically acceptable composition according to claim 3, characterized in that the molar ratio of active components to meglumine is from about 1: 0.3 to about 1: 1.2, about 1: 0.4, or about 1: 1.1.5. The pharmaceutically acceptable composition according to claim 3, characterized in that it contains from about 2.0 to about 11 wt.% Meglumine. The pharmaceutically acceptable composition according to claim 1, additionally containing an agent that inhibits the formation of oxidation products, and preferably the specified agent is selected from ascorbic acid or its pharmaceutically acceptable salt, sodium ascorbate, L-cysteine, N-acetylcysteine (NAC), glutathione (GSH) , Na-EDTA, Na-EDTA-Ca, sodium bisulfite or combinations thereof. 7. Pharma1. Фармацевтически приемлемая композиция, имеющая значение pH от примерно 9,1 до примерно 9,8, содержащая:активные компоненты, включающие карбидопу и, по меньшей мере, примерно 4 мас.% леводопы；аргинин и, необязательно, меглумин,при этом предпочтительно указанная композиция содержит (i) от примерно 4 до примерно 12%
